Evidence map›Paper›PMID 38623386›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia.

Kiran Samra, Georgia Peakman, Amy M MacDougall, Arabella Bouzigues, Caroline V Greaves, Rhian S Convery, John C van Swieten, Lize Jiskoot, Harro Seelaar, Fermin Moreno and 25 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Integrating a motor domain enhances disease severity scales in an FTD-ALS spectrum cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 10 countries.

Kiran SamraDementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.ORCID https://orcid.org/0000-0002-3105-7099
Georgia PeakmanDementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
Amy M MacDougallDepartment of Medical Statistics London School of Hygiene and Tropical Medicine London UK.
Arabella BouziguesDementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
Caroline V GreavesDementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
Rhian S ConveryDementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
John C van SwietenDepartment of Neurology Erasmus Medical Centre Rotterdam the Netherlands.
Lize JiskootDepartment of Neurology Erasmus Medical Centre Rotterdam the Netherlands.
Harro SeelaarDepartment of Neurology Erasmus Medical Centre Rotterdam the Netherlands.
Fermin MorenoCognitive Disorders Unit Department of Neurology Donostia Universitary Hospital Donostia Spain.
Raquel Sanchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit Neurology Service Hospital Clínic Institut d'Investigacións Biomèdiques August Pi I Sunyer University of Barcelona Barcelona Spain.
Robert LaforceClinique Interdisciplinaire de Mémoire Département des Sciences Neurologiques CHU de Québec, and Faculté de Médecine Université Laval, Québec City Québec Canada.
Caroline GraffCenter for Alzheimer Research Division of Neurogeriatrics Department of Neurobiology Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solnavägen Solna Sweden.
Mario MasellisSunnybrook Health Sciences Centre Sunnybrook Research Institute University of Toronto Toronto Ontario Canada.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases University of Toronto Toronto Ontario Canada.
James B RoweDepartment of Clinical Neurosciences University of Cambridge Cambridge UK.
Barbara BorroniNeurology Unit Department of Clinical and Experimental Sciences University of Brescia Piazza del Mercato Brescia Italy.
Elizabeth FingerDepartment of Clinical Neurological Sciences University of Western Ontario London Ontario Canada.
Matthis SynofzikDepartment of Neurodegenerative Diseases Hertie-Institute for Clinical Brain Research and Center of Neurology University of Tübingen Tübingen Germany.
Daniela GalimbertiFondazione Ca' Granda IRCCS Ospedale Policlinico Milan Italy.
Rik VandenbergheLaboratory for Cognitive Neurology Department of Neurosciences KU Leuven Leuven Belgium.
Alexandre de MendonçaFaculty of Medicine University of Lisbon Lisbon Portugal.
Chris R ButlerNuffield Department of Clinical Neurosciences Medical Sciences Division University of Oxford Oxford UK.
Alexander GerhardDivision of Neuroscience and Experimental Psychology Wolfson Molecular Imaging Centre University of Manchester Manchester UK.
Simon DucharmeDepartment of Psychiatry McGill University Health Centre McGill University Montreal Québec Canada.
Isabelle Le BerSorbonne Université Paris Brain Institute - Institut du Cerveau - ICM Inserm U1127, CNRS UMR 7225 AP-HP - Hôpital Pitié-Salpêtrière Paris France.
Pietro TiraboschiFondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy.
Isabel SantanaUniversity Hospital of Coimbra (HUC) Neurology Service, Faculty of Medicine University of Coimbra Coimbra Portugal.
Florence PasquierUniv Lille Lille France.
Johannes LevinDepartment of Neurology Ludwig-Maximilians Universität München Munich Germany.
Markus OttoDepartment of Neurology University of Ulm Ulm Germany.
Sandro SorbiDepartment of Neurofarba University of Florence Firenze Florence Italy.
Jonathan D RohrerDementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.ORCID https://orcid.org/0000-0002-6155-8417
Lucy L RussellDementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
Genetic FTD Initiative (GENFI)
UK Dementia Research Institute · GBErasmus MC · NLGerman Center for Neurodegenerative Diseases · DEBiogipuzkoa Health Research Institute · ESCentre National de la Recherche Scientifique · FRConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESDon Carlo Gnocchi Foundation · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITInserm · FRKarolinska University Hospital · SELondon School of Hygiene & Tropical Medicine · GBMontreal Neurological Institute and Hospital · CASunnybrook Health Science Centre · CAUniversität Ulm · DEUniversité Laval · CAUniversity of Brescia · ITUniversity of Cambridge · GBUniversity of Coimbra · PTUniversity of Lisbon · PTUniversity of Manchester · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionWe aimed to expand the range of the frontotemporal dementia (FTD) phenotypes assessed by the Clinical Dementia Rating Dementia Staging Instrument plus National Alzheimer's Coordinating Center Behavior and Language Domains (CDR plus NACC FTLD).

methodsNeuropsychiatric and motor domains were added to the standard CDR plus NACC FTLD generating a new CDR plus NACC FTLD-NM scale. This was assessed in 522 mutation carriers and 310 mutation-negative controls from the Genetic Frontotemporal dementia Initiative (GENFI).

resultsThe new scale led to higher global severity scores than the CDR plus NACC FTLD: 1.4% of participants were now considered prodromal rather than asymptomatic, while 1.3% were now considered symptomatic rather than asymptomatic or prodromal. No participants with a clinical diagnosis of an FTD spectrum disorder were classified as asymptomatic using the new scales. DISCUSSION: Adding new domains to the CDR plus NACC FTLD leads to a scale that encompasses the wider phenotypic spectrum of FTD with further work needed to validate its use more widely. Highlights: The new Clinical Dementia Rating Dementia Staging Instrument plus National Alzheimer's Coordinating Center Behavior and Language Domains neuropsychiatric and motor (CDR plus NACC FTLD-NM) rating scale was significantly positively correlated with the original CDR plus NACC FTLD and negatively correlated with the FTD Rating Scale (FRS).No participants with a clinical diagnosis in the frontotemporal dementia spectrum were classified as asymptomatic with the new CDR plus NACC FTLD-NM rating scale.Individuals had higher global severity scores with the addition of the neuropsychiatric and motor domains.A receiver operating characteristic analysis of symptomatic diagnosis showed nominally higher areas under the curve for the new scales.

Indexed as

C9orf72frontotemporal dementiageneticsprogranulintau

Identifiers

PMID38623386
PMCPMC11016817
OpenAlexW4394797821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.